Preeclampsia Drugs Market Report 2026

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.37 billion in 2025 to $1.52 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to limited awareness of preeclampsia management, reliance on traditional therapies, lack of advanced monitoring technologies, insufficient hospital infrastructure, low investment in maternal health drugs.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in drug formulations, expansion of healthcare infrastructure, rising demand for outpatient maternal care, integration of digital health solutions, increased R&D in precision medicine for pregnancy complications. Major trends in the forecast period include rising incidence of preeclampsia among pregnant women, development of novel antihypertensive drugs, increased focus on maternal and fetal health monitoring, growth of hospital pharmacy and specialty clinics distribution, adoption of combination therapies for severe cases.

The increasing prevalence of diabetes in pregnant women is anticipated to boost the preeclampsia drug market in the future. Diabetes is a chronic metabolic disorder marked by elevated blood glucose (or blood sugar) levels. Preeclampsia is a dangerous pregnancy complication involving high blood pressure and organ damage. Metformin, a treatment for preeclampsia, is commonly prescribed for pregnant women with preterm preeclampsia. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing number of diabetes cases among pregnant women will fuel the preeclampsia drug market.

Major companies in the preeclampsia medicine market are prioritizing the development of advanced therapies, including small interfering RNA (siRNA) treatments, to meet critical unmet medical needs through innovative mechanisms of action. siRNA investigational therapies represent a category of drugs engineered to silence or inhibit specific genes that drive disease, providing a precise treatment strategy. For example, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had cleared an investigational new drug (IND) application for CBP-4888, their proprietary siRNA therapy for preeclampsia. CBP-4888 is administered subcutaneously and suppresses the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's excessive production of the sFLT1 protein, which circulates into the mother's bloodstream, drives preeclampsia. CBP-4888 helps relieve preeclampsia symptoms like high blood pressure and organ damage, potentially enabling safer prolongation of pregnancy.

In March 2024, ASKA Pharmaceutical Co., Ltd., a Japan-based pharmaceutical firm, collaborated with Red Arrow Therapeutics, Inc., to co-develop a new preeclampsia treatment. This alliance draws on ASKA’s maternal health knowledge and Red Arrow’s pH-responsive nanomedicine platform to create a more precise, safer, and potent option for preeclampsia patients. Red Arrow Therapeutics Inc. is a US biotechnology company specializing in innovative cancer therapies.

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp.

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preeclampsia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the preeclampsia drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized drug formulations, thereby raising production costs for manufacturers. The hospital pharmacy and severe preeclampsia medication segments, particularly in North America and Europe, are most affected due to reliance on imported components. Some positive impacts include incentivizing local production and encouraging manufacturers to invest in domestic drug development and supply chain diversification, which may lead to long-term cost optimization and innovation.

The preeclampsia drugs market research report is one of a series of new reports that provides preeclampsia drugs market statistics, including preeclampsia drugs industry global market size, regional shares, competitors with a preeclampsia drugs market share, detailed preeclampsia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the preeclampsia drugs industry. This preeclampsia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Preeclampsia medications are drugs used to manage and treat preeclampsia, a dangerous pregnancy complication involving high blood pressure and organ damage, such as to the liver and kidneys. Healthcare professionals typically prescribe these drugs to pregnant women with preeclampsia to reduce blood pressure and avoid additional complications.

The primary categories of preeclampsia medications target mild preeclampsia and severe preeclampsia. Mild preeclampsia represents a medical condition affecting certain pregnant women, typically arising after the 20th week of gestation. These drugs support diverse treatments, including blood pressure-lowering agents, corticosteroids, and anticonvulsants, delivered via routes like oral, parenteral, and additional methods. They are accessible through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and more, and serve multiple end-users, including hospitals, specialty clinics, diagnostic centers, and others.

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.